Pharma Journalist -

Thrombolytic Science, LLC (TSI) announced initiation of a Phase 2 clinical trial to confirm the efficacy and safety of its sequential dual-treatment regimen of low-dose tissue…
Read More...

ADMA Biologics, a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the prevention and treatment of…
Read More...

SMi Reports: SMi’s Immuno-Oncology Conference is taking place in just under 4 weeks in London, where industry-leading experts will gather to discuss the potential of Immuno-Therapy as…
Read More...

Pfizer announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-06651600 received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the…
Read More...

AMRI and Metrion Biosciences announced that they have signed a new collaboration agreement. The alliance will promote Metrion's electrophysiology and ion channel screening expertise to…
Read More...

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) seeking accelerated…
Read More...

SGS announced that it has successfully implemented advanced techniques for the collection and use of Peripheral Blood Mononuclear Cells (PBMCs) for early phase clinical trials at its…
Read More...

Key Biologics LLC and Blood Centers of America (BCA) announced an agreement to formalize their existing business relationship and to work collectively to broaden support for cell…
Read More...

United Therapeutics Corporation and MannKind Corporation announced that they have entered into a worldwide exclusive licensing and collaboration agreement for the development and…
Read More...

Sanofi has reached a civil settlement with the U.S. Securities and Exchange Commission (SEC) fully resolving the SEC’s investigation into possible violations of the U.S. Foreign Corrupt…
Read More...